Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

Hadassah Medical Center

Status and phase

Enrolling

Phase 2

Phase 1

Conditions

Breast Cancer

Melanoma

Gastric Cancer

Kidney Cancer

Lung Cancer

Ovarian Cancer

Colorectal Cancer

Treatments

Biological: Autologous or Allogeneic tumor cells

Study type

Interventional

Funder types

Other

Identifiers

NCT00722228

0359-08-HMO-CTIL

Details and patient eligibility

About

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

One of the following metastatic cancers: Melanoma, breast, ovary, colorectal, gastric, lung or kidney
Above 18 years of age
Failure of at least one chemotherapy protocol
Clinical performance status of ECOG 0,1
Absolute neutrophil count greater than 1000/mm3
Serum ALT/AST less than three times the upper limit of normal
Serum creatinine less than or equal to 1.6 mg/dl.
Must be able to understand and sign the Informed Consent document

Exclusion criteria